AI assistant
BSF ENTERPRISE PLC Capital/Financing Update 2025
5346_sha_2025-05-23_25fc2993-9c6b-4011-ba75-9d08405a83e7.html
Capital/Financing Update
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information 
RNS Number : 8777J
BSF Enterprise PLC
23 May 2025
London, 23 May 2025
BSF Enterprise PLC
15p Warrants Amended
BSF Enterprise PLC (LSE:BSFA) (the "Company") a leading innovator in tissue-engineered materials is pleased to announce that it has agreed to amend the warrant instrument issued on 26 April 2022 ("Warrant Instrument") constituting warrants to subscribe for 12,270,217 ordinary shares of one penny each in the capital of the Company at 15p for a period of 3 years (the "Warrants").
The Warrant Instrument has been amended to reduce the exercise price for each of the Warrants from 15p to 7.5p and extend the exercise term by 2 years, to expire on 17 May 2027.
The amendment will not affect any other provisions of the Warrants or any other rights or obligations of the warrantholders.
Contact Information For further information, please visit: www.bsfenterprise.com
For further enquiries , please visit www.bsfenterprise.com or contact:
| BSF Enterprise PLC | |
| Geoff Baker - Executive Director Che Connon - CEO & Director |
|
| Shard Capital (Broker) | |
| Damon Heath Isabella Pierre |
0207 186 9000 0207 186 9927 |
About BSF Enterprise PLC
BSF Enterprise PLC (BSF) develops and commercialises cutting-edge tissue-engineered solutions, including lab-grown leather, cultivated meat, and corneal repair technologies. By leveraging its proprietary scaffold-free platform, BSF aims to deliver sustainable alternatives to traditional materials and meet global demand for environmentally responsible innovations.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
MSCPPUAPAUPAGRP